Research programme: XRN1 inhibitors - Accent Therapeutics
Latest Information Update: 31 Oct 2023
At a glance
- Originator Accent Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Exodeoxyribonuclease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer